Boronic acid-based enzyme inhibitors: a review of recent progress

Curr Med Chem. 2014;21(28):3271-80. doi: 10.2174/0929867321666140601200803.

Abstract

Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Boronic Acids* / pharmacology
  • Boronic Acids* / therapeutic use
  • Histone Deacetylase Inhibitors / pharmacology
  • Histone Deacetylase Inhibitors / therapeutic use
  • Humans
  • Leucine-tRNA Ligase / antagonists & inhibitors
  • Phosphodiesterase Inhibitors / pharmacology
  • Phosphodiesterase Inhibitors / therapeutic use
  • Phosphoric Diester Hydrolases
  • Protease Inhibitors / pharmacology
  • Protease Inhibitors / therapeutic use

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Histone Deacetylase Inhibitors
  • Phosphodiesterase Inhibitors
  • Protease Inhibitors
  • Phosphoric Diester Hydrolases
  • alkylglycerophosphoethanolamine phosphodiesterase
  • Leucine-tRNA Ligase